The Role of Surgery

  • Ulysses RibeiroJr.Email author
  • Fernando Simionato Perrotta


Gastric adenocarcinoma can be divided into intestinal and diffuse, according to Lauren’s classification. Pathological aspects were discussed previously regarding this grouping. The same was done with respect to the biological behavior of these tumors, with diffuse adenocarcinoma presenting a more aggressive behavior comparing to the intestinal type. Essentially, such behavior is the major impact factor in surgical treatment, especially in endoscopic management. Regardless of its classification, the curative treatment of gastric cancer necessarily involves endoscopic resection or surgery even with the several options of neoadjuvant and adjuvant treatment that are available. This chapter describes the surgical management of diffuse gastric cancer, an aggressive disease, and its peculiarities.


Gastric cancer Surgical treatment Diffuse type Endoscopic resection Resection margin Lymphadenectomy 


  1. 1.
    Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.CrossRefGoogle Scholar
  2. 2.
    De Manzoni G, Marrelli D, Baiocchi GL, Morgagni P, Saragoni L, Degiuli M, Donini A, Fumagalli U, Mazzei MA, Pacelli F. The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer. 2017;20:20–30.CrossRefPubMedGoogle Scholar
  3. 3.
    Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C, International Gastric Cancer Linkage C. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010;47:436–44.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Anold D, on behalf of the ESMO Guidelines Committe. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2016;27(Supplement 5):v38–49. Scholar
  5. 5.
    Wang SY, Yeh CN, Lee HL, et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol. 2009;16:2738–43.CrossRefPubMedGoogle Scholar
  6. 6.
    Sun Z, Li DM, Wang ZN, et al. Prognostic significance of microscopic positive margins for gastric cancer patients with potentially curative resection. Ann Surg Oncol. 2009;16:3028–37.CrossRefPubMedGoogle Scholar
  7. 7.
    Bickenbach KA, Gonen M, Strong V, Brennan MF, Coit DG. Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol. 2013;20:2663–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Squires MH 3rd, Kooby DA, Pawlik DA, et al. Utility of the proximal margin frozen section for resection of gastric adenocarcinoma: a 7-institution study of the US Gastric Cancer Collaborative. Ann Surg Oncol. 2014;21:4202–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Marrelli D, Pedrazzani C, Morgagni P, de Manzoni G, Pacelli F, Coniglio A, et al. Italian Research Group for Gastric Cancer. Changing clinical and pathological features of gastric cancer over time. Br J Surg. 2011;98:1273–83.Google Scholar
  10. 10.
    Shen P, Stewart JH, Levine EA. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: overview and rationale. Curr Probl Cancer. 2009;33:125–41.CrossRefPubMedGoogle Scholar
  11. 11.
    Roviello F, Caruso S, Neri A, Marrelli D. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. Eur J Surg Oncol. 2013;39:1309–16.CrossRefPubMedGoogle Scholar
  12. 12.
    Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F, Elias D. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17:2370–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Marrelli D, Polom K, de Manzoni G, Morgagni P, Baiocchi GL, Roviello F. Multimodal treatment of gastric cancer in the west: where are we going? World J Gastroenterol. 2015;21(26):7954–69.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Bozzetti F, Yu W, Baratti D, Kusamura S, Deraco M. Locoregional treatment of peritoneal carcinomatosis from gastric cancer. J Surg Oncol. 2008;98:273–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg. 2005;92:370–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR. Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol. 2004;10:2727–30.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL. A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14:2702–13.CrossRefPubMedGoogle Scholar
  18. 18.
    Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Miwa S, Tsuneyama K, Takano Y. Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol. 2006;60:273–7.CrossRefPubMedGoogle Scholar
  19. 19.
    Zilberstein B, Malheiros C, Lourenço LG, Kassab P, Jacob CE, Weston AC, Bresciani CJC, Castro O, Gama-Rodrigues J, de Consenso G. Consenso brasileiro sobre câncer gástrico: diretrizes para o câncer gástrico no Brasil. ABCD Arq Bras Cir Dig. 2013;26(1):2–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Moehler M, Baltin CTH, Ebert M, Fischbach W, Gockel I, Grenacher L, et al. International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer. 2015;18:550–63.CrossRefPubMedGoogle Scholar
  21. 21.
    Kim W, Kim HH, Han SU, et al. Decreased morbidity of laparoscopic distal gastrectomy compared with open distal gastrectomy for stage I gastric cancer: short-term outcomes from a multicenter randomized controlled trial (KLASS-01). Ann Surg. 2016;263:28–35.CrossRefPubMedGoogle Scholar
  22. 22.
    Hu Y, Huang C, Sun Y, et al. Morbidity and mortality of laparoscopic versus open D2 distal gastrectomy for advanced gastric cancer: a randomized controlled trial. J Clin Oncol. 2016;34:1350–7. Scholar
  23. 23.
    Takeichi M. Morphogenetic roles of classic cadherins. Curr Opin Cell Biol. 1995;7:619–27.CrossRefPubMedGoogle Scholar
  24. 24.
    Geisbrecht ER, Montell DJ. Myosin VI is required for E-cadherin-mediated border cell migration. Nat Cell Biol. 2002;4:616–20.CrossRefPubMedGoogle Scholar
  25. 25.
    Machado JC, Oliveira C, Carvalho R, et al. E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene. 2001;20:1525–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Berx G, Cleton-Jansen AM, Nollet F, et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 1995;14:6107–15.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    van der Post RS, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52:361–74.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Chen Y, Kingham K, Ford JM, et al. A prospective study of total gastrectomy for CDH1-positive hereditary diffuse gastric cancer. Ann Surg Oncol. 2011;18:2594–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Wang Z, Xu J, Shi Z, Shen X, Luo T, Bi J, Nie M. Clinicopathologic characteristics and prognostic of gastric cancer in young patients. Scand J Gastroenterol. 2016;51(9):1043–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Pernot S, Voron T, Perkins G, Lagorce-Pages C, Berger A, Taieb J. Signet-ring cell carcinoma of the stomach: impact on prognosis and specific therapeutic challenge. World J Gastroenterol. 2015;21(40):11428–38.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–62.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Dassen AE, Lemmens VE, van de Poll-Franse LV, et al. Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer. 2010;46(6):1101–10.CrossRefPubMedGoogle Scholar
  33. 33.
    Marqués-Lespier JM, González-Pons M, Cruz-Correa M. Current perspectives on gastric Cancer. Gastroenterol Clin N Am. 2016;45(3):413–28.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ulysses RibeiroJr.
    • 1
    Email author
  • Fernando Simionato Perrotta
    • 2
  1. 1.University of São Paulo School of Medicine, Instituto do Câncer do Estado de São Paulo, ICESP-HCFMUSPSão PauloBrazil
  2. 2.Department of GastroenterologyUniversity of São Paulo School of MedicineSão PauloBrazil

Personalised recommendations